Ellisek-S

Ellisek-S Uses, Dosage, Side Effects, Food Interaction and all others data.

Ellisek-S Citrate belongs to the anti-cough medicines of central action. It exerts expectorant, moderate bronchodilating and anti-inflammatory action. Ellisek-S Citrate also increases the spirometery indexes and blood oxygenation. It is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. The active metabolites of Ellisek-S Citrate have also antitussive action.

Ellisek-S
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ellisek-S
Generic	Butamirate
Butamirate Other Names	Butamirate
Type
Formula	C₁₈H₂₉NO₃
Weight	Average: 307.434 Monoisotopic: 307.214743798
Groups	Experimental
Therapeutic Class	Cough suppressant
Manufacturer
Available Country	Greece
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ellisek-S Citrate is used for acute cough of any etiology, suppression of pre-& post-operative cough in surgery & bronchoscopy and suppression of whooping cough.

Ellisek-S is also used to associated treatment for these conditions: Cough

Dosage

Ellisek-S dosage

Tablet:

Adult: 2-3 tablets daily at 8 to 12 hours intervals,
Adolescents over 12 years old: 1-2 tablets daily.

Syrup:

Children (3-6 years): 5 ml 3 times daily,
Children (6-12 years): 10 ml 3 times daily,
Adolescent: 15 ml 3 times daily,
Adult: 15 ml 4 times daily.

PediatricDrops:

Children (1-3 years): 0.75 ml 4 times daily,
Children (2 months-1 year): 0.50 ml 4 times daily.

Side Effects

Tolerance of Ellisek-S Citrate is good. Adverse reactions such as rash, nausea, diarrhea and vertigo have been observed in a few rare cases, resolving after dose reduction or treatment withdrawal.

Precaution

Avoid simultanous administration of expectorants. Minor influence on the ability to drive & use machines. Avoid during pregnancy (1st 3 months) & lactation.

Tablet: Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

Syrup: Sorbitol: Rare hereditary problems of fructose intolerance. Contains ethanol.

Interaction

Avoid use with expectorants.

Pregnancy & Breastfeeding use

Ellisek-S Citrate should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Ellisek-S Citrate administration during breast feeding should be carefully weighed against the risks.

Contraindication

Ellisek-S Citrate is contraindicated in patients with known hypersensitivity to any component of the formulation.

Acute Overdose

Accidental overdose with Ellisek-S Citrate can cause the following symptoms: drowsiness, nausea, vomiting, diarrhea, loss of balance and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.